C. Veyret

发表

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.

J. Bonneterre, A. Monnier, I. van Praagh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

J. Picquenot, F. Clatot, A. Dujon, 2015, International journal of cancer.

Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial

M. Namer, J. Bonneterre, A. Monnier, 2007, British Journal of Cancer.

Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)

M. Héry, T. Delozier, M. Namer, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Polyadenylic–Polyuridylic Acid Plus Locoregional Radiotherapy Versus Chemotherapy with CMF in Operable Breast Cancer: a 14 Year Follow-up Analysis of a Randomized Trial of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)

T. Delozier, A. Laplanche, P. Fargeot, 2000, Breast Cancer Research and Treatment.

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

X. Pivot, F. Bidard, J. Pierga, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

F. Puglisi, G. Romieu, G. von Minckwitz, 2014, The Lancet. Oncology.

Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis

B. Asselain, C. Veyret, P. Bastit, 1987, Cancer.

Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer.

F. Clatot, O. Rigal, M. Bubenheim, 2020, European journal of cancer.

Value of CA 15-3 determination in the initial management of breast cancer patients.

D. Georgescu, C. Veyret, C. Guillemet, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].

M. Espié, X. Pivot, J. Pierga, 2012, Bulletin du cancer.

Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: a double-blind randomized study. European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group.

R. Paridaens, R. Sylvester, J. Julien, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: Preliminary results of a double-blind randomized study of the eortic breast cancer cooperative group

J. Klijn, R. Paridaens, R. Sylvester, 1990, Journal of Steroid Biochemistry and Molecular Biology.

Comparison of HER2 extra cellular domain (ECD) serum level at the time of metastasis with HER2 status modification between primary breast cancers and their respective metastases

J. Picquenot, E. Blot, C. Veyret, 2008 .

[Routine use of serial plasmatic CA 15-3 determinations during the follow-up of patients treated for breast cancer. Evaluation as factor of early diagnosis of recurrence].

C. Veyret, A. Loeb, A. Chevrier, 2008, Annales de Biologie Clinique.

Neoadjuvant weekly paclitaxel, and epirubicin (PE) in patients with inflammatory and T4 breast cancer (IBC-T4BC): Result of a VAR Cancer Society tria

C. Veyret, L. Cals, X. Tchiknavorian, 2004 .

Inflammatory breast cancer outcome with epirubicin‐based induction and maintenance chemotherapy

P. Fumoleau, P. Fargeot, P. Kerbrat, 2006, Cancer.

Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.

T. Delozier, M. Campone, T. Petit, 2009 .

Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881

M. Piccart, L. Mauriac, J. Jassem, 1998 .

Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial

T. Delozier, J. Julien, C. Veyret, 2005, Breast Cancer Research and Treatment.

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel

C. Meisner, N. Harbeck, Marcus Schmidt, 2011, BMC Cancer.

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

J. Machiels, F. Penault-Llorca, B. Asselain, 2012, The oncologist.

Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment.

F. Eustache, B. Clarisse, F. Joly, 2016, The oncologist.

Intensive chemotherapy for inflammatory breast cancer: how much clinical value ?

J. Julien, C. Veyret, J. d'Anjou, 1994 .

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

M. Espié, X. Pivot, J. Pierga, 2011, British journal of clinical pharmacology.

C. Meisner, N. Harbeck, G. von Minckwitz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer

B. Asselain, L. Mauriac, P. Fumoleau, 2011, British Journal of Cancer.

CxCR4 Membrane Expression in Node‐Negative Breast Cancer

J. Picquenot, E. Blot, C. Veyret, 2008, The breast journal.

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.

J. Klijn, M. Piccart, L. Mauriac, 2000, Journal of the National Cancer Institute.

A higher body mass index and fat mass are factors predictive of docetaxel dose intensity.

Romain Modzelewski, Olivier Rigal, R. Modzelewski, 2013, Anticancer research.

Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy

F. Clatot, E. Blot, M. Ouvrier, 2009, Journal of Neuro-Oncology.

Port catheter versus peripherally inserted central catheter for postoperative chemotherapy in early breast cancer: a retrospective analysis of 448 patients

F. Clatot, O. Rigal, D. Georgescu, 2016, Supportive Care in Cancer.

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207).

J. Lemonnier, B. Thürlimann, H. Hawle, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

A. Giobbie-Hurder, P. Neven, R. Gelber, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node‐positive, early‐stage, invasive breast carcinoma undergoing breast‐conserving surgery

A. Courdi, A. Monnier, D. Berton‐Rigaud, 2005, Cancer.

Anastrozole and goserelin combination as first treatment for premenopausal receptor positive advanced or metastatic breast cancer: A phase II trial.

M. Campone, C. Veyret, H. Roché, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PP-8-1 Combined estroyen suppression and receptor (ER) blockade by buserelin (LHRH-A) and tamoxifen (TAM) in premenopausal metastatic breast cancer: Preliminary results of a 3-arm randomized study (EORTC 10881)

J. Klijn, M. Piccart, J. Garcia-conde, 1996 .

Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors.

J. Picquenot, F. Clatot, S. Laberge, 2015, American journal of clinical pathology.

403PPHASE II STUDY EVALUATING ORAL VINORELBINE AS A SINGLE-AGENT AS FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER PATIENTS WITH BONE METASTASES (NORBREAST-228 TRIAL): FIRST EFFICACY RESULTS.

E. Espinosa, M. Benasso, M. Błasińska-Morawiec, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor

F. Jardin, J. Picquenot, F. Clatot, 2016, Oncotarget.

Abstract P1-13-13: First planned efficacy analysis of the NNBC 3-Europe trial: Addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients.

C. Meisner, N. Harbeck, C. Thomssen, 2012 .

Baseline cognitive functions among elderly patients with localised breast cancer.

F. Eustache, B. Clarisse, F. Joly, 2014, European journal of cancer.

Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression

L. Mauriac, M. Mouret-Reynier, T. Bachelot, 2007 .

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.

B. Asselain, M. Campone, T. Petit, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial

I. Bièche, E. Brain, M. Debled, 2015, Breast Cancer Research and Treatment.

Individualized Prediction of Menses Recovery After Chemotherapy for Early‐stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials

J. Lemonnier, M. Campone, B. Pistilli, 2019, Clinical breast cancer.

Use of everolimus in advanced hormone receptor–positive metastatic breast cancer in a multicenter national observational study.

T. Petit, P. Arveux, B. Pistilli, 2017 .

Abstract P3-06-08: Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)

M. Oestergaard, F. Puglisi, G. Romieu, 2015 .

Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label study

H. Bonnefoi, G. Romieu, P. Viens, 2008 .

Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer.

F. Eustache, B. Clarisse, F. Joly, 2018, The oncologist.

Baseline cognitive functions among elderly patients with localised breast cancer.

F. Eustache, B. Clarisse, F. Joly, 2014, European journal of cancer.

353OEFFICACY AND SAFETY IN TANIA, A RANDOMISED PHASE III TRIAL OF CONTINUED OR REINTRODUCED BEVACIZUMAB (BEV) AFTER 1ST-LINE BEV FOR HER2-NEGATIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC).

F. Puglisi, G. Romieu, G. von Minckwitz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.